Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
ACS Comb Sci ; 18(10): 611-615, 2016 10 10.
Article in English | MEDLINE | ID: mdl-27494431

ABSTRACT

Small molecule selectivity is an essential component of candidate drug selection and target validation. New technologies are required to better understand off-target effects, with particular emphasis needed on broad protein profiling. Here, we describe the use of a tritiated chemical probe and a 9000 human protein microarray to discern the binding selectivity of an inhibitor of the mRNA decapping scavenger enzyme DcpS. An immobilized m7GTP resin was also used to assess the selectivity of a DcpS inhibitor against mRNA cap-associated proteins in whole cell extracts. These studies confirm the exquisite selectivity of diaminoquinazoline DcpS inhibitors, and highlight the utility of relatively simple protein microarray and affinity enrichment technologies in drug discovery and chemical biology.


Subject(s)
Endoribonucleases/analysis , Molecular Probes/chemistry , Quinazolines/chemistry , RNA Cap-Binding Proteins/analysis , Catalysis , Cells, Cultured , Endoribonucleases/antagonists & inhibitors , Endoribonucleases/genetics , Humans , Leukocytes, Mononuclear/chemistry , Protein Array Analysis , RNA, Messenger/genetics , Survival of Motor Neuron 2 Protein/analysis , Tritium
2.
EMBO Mol Med ; 5(7): 1103-18, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23740718

ABSTRACT

Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes progressive muscle weakness, which primarily targets proximal muscles. About 95% of SMA cases are caused by the loss of both copies of the SMN1 gene. SMN2 is a nearly identical copy of SMN1, which expresses much less functional SMN protein. SMN2 is unable to fully compensate for the loss of SMN1 in motor neurons but does provide an excellent target for therapeutic intervention. Increased expression of functional full-length SMN protein from the endogenous SMN2 gene should lessen disease severity. We have developed and implemented a new high-throughput screening assay to identify small molecules that increase the expression of full-length SMN from a SMN2 reporter gene. Here, we characterize two novel compounds that increased SMN protein levels in both reporter cells and SMA fibroblasts and show that one increases lifespan, motor function, and SMN protein levels in a severe mouse model of SMA.


Subject(s)
Drug Discovery , Muscular Atrophy, Spinal/drug therapy , Small Molecule Libraries/therapeutic use , Survival of Motor Neuron 2 Protein/genetics , Up-Regulation/drug effects , Animals , Cells, Cultured , Fibroblasts/drug effects , Fibroblasts/metabolism , Fibroblasts/pathology , High-Throughput Screening Assays , Humans , Mice , Muscular Atrophy, Spinal/genetics , Muscular Atrophy, Spinal/physiopathology , RNA, Messenger/genetics , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Survival of Motor Neuron 1 Protein/analysis , Survival of Motor Neuron 1 Protein/genetics , Survival of Motor Neuron 2 Protein/analysis
3.
Electrophoresis ; 30(7): 1102-10, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19373809

ABSTRACT

We established a universal multiplex PCR and CE to calculate the copy number of survival motor neuron (SMN1 and SMN2) genes for clinical screening of spinal muscular atrophy (SMA). In this study, one universal fluorescent primer was designed and applied for multiplex PCR of SMN1, SMN2 and two internal standards (CYBB and KRIT1). These amplicons were separated by conformation sensitive CE. Mixture of hydroxyethyl cellulose and hydroxypropyl cellulose were used in this CE system. Our method provided the potential to separate two 390-bp PCR products that differ in a single nucleotide. Differentiation and quantification of SMN1 and SMN2 are essential for clinical screening of SMA patients and carriers. The DNA samples included 22 SMA patients, 45 parents of SMA patients (obligatory carriers) and 217 controls. For evaluating accuracy, those 284 samples were blind-analyzed by this method and denaturing high pressure liquid chromatography (DHPLC). Eight of the total samples showed different results. Among them, two samples were diagnosed as having only SMN2 gene by DHPLC, however, they contained both SMN1 and SMN2 by our method. They were further confirmed by DNA sequencing. Our method showed good agreement with the DNA sequencing. The multiplex ligation-dependent probe amplification (MLPA) was used for confirming the other five samples, and showed the same results with our CE method. For only one sample, our CE showed different results with MLPA and DNA sequencing. One out of 284 samples (0.35%) belonged to mismatching. Our method provided a better accurate method and convenient method for clinical genotyping of SMA disease.


Subject(s)
Electrophoresis, Capillary/methods , Gene Dosage , Muscular Atrophy, Spinal/diagnosis , Polymerase Chain Reaction/methods , Survival of Motor Neuron 1 Protein/genetics , Cellulose/analogs & derivatives , Cellulose/chemistry , Genetic Testing/methods , Humans , Sensitivity and Specificity , Survival of Motor Neuron 1 Protein/analysis , Survival of Motor Neuron 2 Protein/analysis , Survival of Motor Neuron 2 Protein/genetics , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL